No. According to FDA-derived drug labeling information, fluoxetine and pimozide should not be used together. This combination is classified as contraindicated, which is the highest level of caution and means the risks of taking these two medications at the same time outweigh any potential benefit. The primary concern is a condition called QT interval prolongation, which affects how your heart's electrical system works.
The source record for this interaction comes from NLP-processed FDA drug labeling for fluoxetine and classifies the fluoxetine-pimozide combination as contraindicated. Contraindicated means your healthcare providers should avoid prescribing this pair together under standard circumstances. The documented concern is QT interval prolongation—a change in the electrical activity of your heart that can be detected on an electrocardiogram (ECG or EKG).
This is not a mild or manageable interaction. It is not a situation where careful monitoring might allow both drugs to be used safely. Instead, it represents a documented safety signal serious enough that the drug labeling advises against concurrent use.
Your heart beats because electrical signals move through heart muscle in a precise sequence. An electrocardiogram (ECG) measures these signals and divides them into labeled segments. The QT interval is the time it takes for a particular phase of the heart's electrical cycle to complete—from when the ventricles (the heart's lower chambers) start to contract until they finish relaxing.
When the QT interval becomes abnormally long, it is called prolongation. A prolonged QT interval can disrupt the orderly electrical rhythm of the heart and create conditions that allow dangerous, chaotic heartbeats to start. One of these dangerous rhythms is called torsades de pointes, which can cause fainting, loss of consciousness, or even sudden cardiac death in severe cases.
The source record specifies that the mechanism of this interaction is QT interval prolongation. This means that the combination of fluoxetine and pimozide carries a documented risk that together they may lengthen the QT interval more than either drug alone.
Different medications can prolong the QT interval through different pathways in the body. The source record does not specify the exact cellular or molecular mechanism—for instance, whether both drugs affect the same potassium channels in heart muscle or whether they affect different pathways that add up. What is documented is that this pair carries a recognized QT prolongation risk.
Pimozide is an antipsychotic medication—a drug used to treat psychotic conditions like schizophrenia. Antipsychotic medications, particularly older or "typical" antipsychotics like pimozide, are known to carry inherent QT prolongation risk. This risk is built into pimozide's pharmacology and is documented in its FDA labeling.
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI), a class of antidepressant medications. SSRIs are generally considered cardiac-safe at standard doses, but fluoxetine, particularly at higher doses or in certain combinations, has been associated with QT interval effects in drug labeling. When fluoxetine is paired with a drug like pimozide that already carries QT risk, the concern is additive or synergistic—meaning the two risks combine, potentially making the cardiac danger more serious.
Many medications can affect the QT interval by altering how potassium, calcium, or sodium move in and out of heart muscle cells. Some medications inhibit specific ion channels—essentially blocking the normal flow of these charged particles. This slowing or blocking can lengthen the QT interval. When multiple drugs that affect these pathways are used together, the effects can add up.
However, the source record specifies the documented interaction as QT interval prolongation. The exact cellular mechanism by which fluoxetine and pimozide together produce this effect is not specified in the source material.
If you are currently taking pimozide for a psychotic disorder or taking fluoxetine for depression or anxiety, this interaction becomes relevant to your care. The contraindication applies regardless of your age, gender, or baseline heart health, because the risk is a documented pharmacological one.
Certain groups may face heightened risk from QT prolongation in general—for example, people with a personal or family history of long QT syndrome, people taking other QT-prolonging medications, people with electrolyte imbalances (low potassium or magnesium), people with heart failure, or people taking certain other cardiac medications. If any of these factors apply to you, discussing them with your doctor or pharmacist is especially important. However, the baseline contraindication between fluoxetine and pimozide stands on its own.
Imagine you have been stable on pimozide for schizophrenia for two years. Your primary care doctor, not fully aware of your psychiatric medication, suggests fluoxetine for depression. Before you begin fluoxetine, your pharmacist reviews your medication list, sees pimozide, and alerts both you and your doctor to the contraindication. Your doctor and psychiatrist then coordinate to explore alternatives—perhaps a different class of antidepressant that does not carry the same QT risk, or a different approach to your depression management altogether. This is the ideal scenario: the interaction is caught before you are exposed to both drugs simultaneously.
Suppose you are already taking both fluoxetine and pimozide because they were prescribed by different specialists who did not communicate, or because the interaction was missed during a medication review. Your pharmacist discovers the combination during a routine refill. The appropriate next step is not for you to stop either drug on your own, but to contact both your prescribing doctors immediately to discuss the interaction, your clinical need for each medication, and safer alternatives. This situation underscores why maintaining an accurate, up-to-date medication list and using a single pharmacy when possible are protective measures.
If you are taking or considering taking either fluoxetine or pimozide, here are questions and points for conversation:
The information in this article is sourced primarily from FDA drug labeling data processed for checkdruginteractions.com. This is an educational explanation layer, not a substitute for professional medical advice. If you take fluoxetine, pimozide, or any other medication, use checkdruginteractions.com to check your full medication list for documented interactions, and confirm all medication decisions with your pharmacist or physician. Do not start, stop, or change any medication without professional guidance.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Learn about the documented moderate interaction between atorvastatin and gemfibrozil, how OATP1B1 transporter inhibition affects drug lev...
Furosemide is contraindicated with lithium due to reduced renal clearance and high toxicity risk. Learn why and what to discuss with your...
Spironolactone increases digoxin levels and half-life, raising the risk of digitalis toxicity. Learn what this major interaction means.